DGX Stock Up on New Blood Test Development Deal With MD Anderson

Quest Diagnostics (DGX) will collaborate with MD Anderson Cancer Center to develop and validate a blood test for assessing elevated cancer risk, based on MD Anderson's MCaST model; DGX shares rose 2.6% following the announcement, adding to a 31.3% gain over the past year. The collaboration aims to address the unmet need for convenient and affordable cancer screenings, particularly for less common cancers, with potential commercialization in North America targeted for 2026. The global cancer diagnostics market is projected to grow at a CAGR of 6.1% through 2030, supporting a positive outlook for DGX.

Analysis

Quest Diagnostics (DGX) has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center to co-develop and validate a blood test for assessing elevated cancer risk, leveraging MD Anderson's Multi-Cancer Stratification Test (MCaST) model. This development spurred a 2.6% rise in DGX shares, which have already appreciated 31.3% over the past year, significantly outpacing the industry's 3.6% growth. The initiative seeks to address the low uptake of preventive cancer screenings, with only 51% of U.S. adults reporting routine screenings last year, and the lack of effective tests for certain deadly cancers like pancreatic. Quest Diagnostics aims for potential commercialization of the test in North America by 2026, assuming successful validation. This venture is supported by robust industry prospects, as the global cancer diagnostics market, valued at $109.6 billion in 2024, is projected to expand at a 6.1% CAGR through 2030. Quest Diagnostics, with a current market capitalization of $20.12 billion, also recently launched AD-Detect, a blood test for Alzheimer's disease, underscoring its commitment to diagnostic innovation. The company's 2025 earnings are anticipated to grow 8.6% over 2024, and it has demonstrated consistent performance with an average earnings beat of 2% over the trailing four quarters. The market sentiment regarding this collaboration is strongly positive, reflecting optimism about its potential impact.

Key Decisions for Investors

• Investors should closely monitor the progress of the MCaST-based blood test through its development, validation, and potential commercialization by 2026, as this represents a significant growth opportunity for Quest Diagnostics.
• Consider the company's broader innovation pipeline, including the recent Alzheimer's test and this new cancer diagnostic initiative, as key potential drivers for sustained revenue growth and market share expansion in the expanding diagnostics sector.
• Evaluate Quest Diagnostics' current valuation in light of its 31.3% stock rally over the past year and its Zacks Rank #3 (Hold), weighing the positive long-term prospects from new product developments against near-term market sentiment and the projected 8.6% earnings growth for 2025.